{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:13:49Z","timestamp":1788135229705,"version":"build-2803163510"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002565","name":"Alzheimer's Drug Discovery Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012479","name":"Weston Brain Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Aging"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.neurobiolaging.2020.12.011","type":"journal-article","created":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T18:54:35Z","timestamp":1608144875000},"page":"22-31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Associations between brain amyloid accumulation and the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers"],"prefix":"10.1016","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9635-107X","authenticated-orcid":false,"given":"Michael","family":"Ouk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Che-Yuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer S.","family":"Rabin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodi D.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5582-1776","authenticated-orcid":false,"given":"Joel","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Masellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6571-5531","authenticated-orcid":false,"given":"Richard H.","family":"Swartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista L.","family":"Lanct\u00f4t","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra E.","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Swardfager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s40478-019-0718-2","article-title":"Divergence in the activity of the N- and C- catalytic domains of ACE1 - implications for the role of the renin-angiotensin system in Alzheimer\u2019s disease","volume":"7","author":"Al Mulhim","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib2","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.3233\/JAD-150831","article-title":"Effects of hypertension and anti-hypertensive treatment on amyloid-\u03b2 (A\u03b2) plaque load and A\u03b2-synthesizing and A\u03b2-degrading enzymes in frontal cortex","volume":"50","author":"Ashby","year":"2016","journal-title":"J.\u00a0Alzheimer\u2019s Dis."},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib3","doi-asserted-by":"crossref","first-page":"e0206705","DOI":"10.1371\/journal.pone.0206705","article-title":"The association of multiple anti-hypertensive medication classes with Alzheimer\u2019s disease incidence across sex, race, and ethnicity","volume":"13","author":"Barthold","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib4","first-page":"1","article-title":"Fitting linear mixed-effects models using lme4","volume":"1","author":"Bates","year":"2015","journal-title":"J.\u00a0Stat. Softw."},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib5","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1161\/01.HYP.0000123072.34629.57","article-title":"Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR\u03b3\u2013modulating activity","volume":"43","author":"Benson","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3233\/JAD-190362","article-title":"The relationship between the use of antihypertensive drugs and the incidence of dementia in general practices in Germany","volume":"70","author":"Bohlken","year":"2019","journal-title":"J.\u00a0Alzheimer\u2019s Dis."},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib7","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1161\/HYPERTENSIONAHA.112.195511","article-title":"Hypertension induces brain \u03b2-amyloid accumulation, cognitive impairment, and memory deterioration through activation of receptor for advanced glycation end products in brain vasculature","volume":"60","author":"Carnevale","year":"2012","journal-title":"Hypertens. (Dallas, Tex. 1979)"},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib8","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","article-title":"Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure","volume":"42","author":"Chobanian","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib9","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1089\/rej.2009.0944","article-title":"Protective effects of intranasal Losartan in the APP\/PS1 transgenic mouse model of Alzheimer disease","volume":"13","author":"Danielyan","year":"2010","journal-title":"Rejuvenat. Res."},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib10","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.2174\/1567205013666160401115127","article-title":"Alzheimer\u2019s disease genetic risk factor APOE-\u03b54 also affects normal brain function","volume":"13","author":"Di Battista","year":"2016","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib11","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1474-4422(19)30393-X","article-title":"Antihypertensive medications and risk for incident dementia and Alzheimer\u2019s disease: a meta-analysis of individual participant data from prospective cohort studies","volume":"19","author":"Ding","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib12","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s13311-019-00723-6","article-title":"Intranasal Losartan decreases perivascular beta amyloid, inflammation, and the decline of neurogenesis in hypertensive rats","volume":"16","author":"Drews","year":"2019","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib13","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/ajh.2009.119","article-title":"Effects of antihypertensive therapy on cognitive decline in Alzheimer\u2019s disease","volume":"22","author":"Duron","year":"2009","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib14","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.3233\/JAD-170238","article-title":"Antihypertensive treatment is associated with MRI-derived markers of neurodegeneration and impaired cognition: a propensity-weighted cohort study","volume":"59","author":"Edwards","year":"2017","journal-title":"J.\u00a0Alzheimer\u2019s Dis."},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib15","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00401-019-02098-6","article-title":"ACE2 activation protects against cognitive decline and reduces amyloid pathology in the Tg2576 mouse model of Alzheimer\u2019s disease","volume":"139","author":"Evans","year":"2020","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib16","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1586\/ern.09.89","article-title":"Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors","volume":"9","author":"Fournier","year":"2009","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/ajh\/hpu086","article-title":"Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker","volume":"28","author":"Furuhashi","year":"2015","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib18","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1212\/WNL.0b013e3182a351d4","article-title":"Antihypertensive medication use and risk of cognitive impairment: the Honolulu-Asia Aging Study","volume":"81","author":"Gelber","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib19","first-page":"95","article-title":"Effects of vascular risk factors, statins, and antihypertensive drugs on PiB deposition in cognitively normal subjects","volume":"2","author":"Glodzik","year":"2016","journal-title":"Alzheimer\u2019s Dement. (Amsterdam, Netherlands)"},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib20","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/bcp.12511","article-title":"Angiotensin receptor blockers and risk of dementia: cohort study in UK Clinical Practice Research Datalink","volume":"79","author":"Goh","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib21","volume":"1","author":"G\u00f3mez-Rubio","year":"2017"},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib22","doi-asserted-by":"crossref","first-page":"4637","DOI":"10.1073\/pnas.0308627101","article-title":"Default-mode network activity distinguishes Alzheimer\u2019s disease from healthy aging: evidence from functional MRI","volume":"101","author":"Greicius","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnagi.2013.00098","article-title":"Neprilysin and A\u03b2 clearance: impact of the APP intracellular domain in NEP regulation and implications in Alzheimer\u2019s disease","volume":"5","author":"Grimm","year":"2013","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib24","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1212\/WNL.0000000000004643","article-title":"In\u00a0vivo staging of regional amyloid deposition","volume":"89","author":"Grothe","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib25","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1001\/archneurol.2012.1010","article-title":"Impact of angiotensin receptor blockers on Alzheimer disease neuropathology in a large brain autopsy series","volume":"69","author":"Hajjar","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib26","doi-asserted-by":"crossref","first-page":"37644","DOI":"10.1074\/jbc.M508460200","article-title":"Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor","volume":"280","author":"Hemming","year":"2005","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib27","first-page":"1","article-title":"Memory is preserved in older adults taking AT1 receptor blockers","volume":"9","author":"Ho","year":"2017","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib28","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.0b013e3182840bbe","article-title":"Brain \u03b2-amyloid load approaches a plateau","volume":"80","author":"Jack","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib29","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.3233\/JAD-171119","article-title":"The coming of age of the angiotensin hypothesis in Alzheimer\u2019s disease: progress toward disease prevention and treatment?","volume":"62","author":"Kehoe","year":"2018","journal-title":"J.\u00a0Alzheimers. Dis."},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib30","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/1756285609103483","article-title":"Blood pressure and dementia\u2014a comprehensive review","volume":"2","author":"Kennelly","year":"2009","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib31","doi-asserted-by":"crossref","first-page":"7428","DOI":"10.1523\/JNEUROSCI.1056-19.2019","article-title":"Reciprocal predictive relationships between amyloid and tau biomarkers in Alzheimer\u2019s disease progression: an empirical model","volume":"39","author":"Krance","year":"2019","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib32","doi-asserted-by":"crossref","first-page":"70","DOI":"10.2967\/jnumed.112.109009","article-title":"Amyloid-\u03b2 imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods","volume":"54","author":"Landau","year":"2013","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib33","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2967\/jnumed.114.148981","article-title":"Measurement of longitudinal \u03b2-amyloid change with 18F-florbetapir PET and standardized uptake value ratios","volume":"56","author":"Landau","year":"2015","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib34","doi-asserted-by":"crossref","first-page":"e1002660","DOI":"10.1371\/journal.pmed.1002660","article-title":"Nilvadipine in mild to moderate Alzheimer disease: a randomised controlled trial","volume":"15","author":"Lawlor","year":"2018","journal-title":"PLoS Med."},{"issue":"8","key":"10.1016\/j.neurobiolaging.2020.12.011_bib35","first-page":"1","article-title":"Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension","author":"Li","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib36","doi-asserted-by":"crossref","first-page":"b5465","DOI":"10.1136\/bmj.b5465","article-title":"Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis","volume":"340","author":"Li","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib37","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.neuron.2017.11.013","article-title":"ApoE4 accelerates early seeding of amyloid pathology","volume":"96","author":"Liu","year":"2017","journal-title":"Neuron"},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib38","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1016\/S0140-6736(17)31363-6","article-title":"Dementia prevention, intervention, and care","volume":"390","author":"Livingston","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib39","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jamaneurol.2019.2214","article-title":"Staging \u03b2-amyloid pathology with amyloid positron emission tomography","volume":"76","author":"Mattsson","year":"2019","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib40","doi-asserted-by":"crossref","first-page":"535816","DOI":"10.4061\/2011\/535816","article-title":"The default mode network in healthy aging and Alzheimer's disease","volume":"2011","author":"Mevel","year":"2011","journal-title":"Int. J. Alzheimer's Dis."},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib41","first-page":"163","article-title":"Angiotensin-converting enzyme levels and activity in Alzheimer\u2019s disease: differences in brain and CSF ACE and association with ACE1 genotypes","volume":"1","author":"Miners","year":"2009","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib42","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.bbrc.2008.08.032","article-title":"Telmisartan prevented cognitive decline partly due to PPAR-\u03b3 activation","volume":"375","author":"Mogi","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib43","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.3233\/JAD-180943","article-title":"Observational study of brain atrophy and cognitive decline comparing a sample of community-dwelling people taking angiotensin converting enzyme inhibitors and angiotensin receptor blockers over time","volume":"68","author":"Moran","year":"2019","journal-title":"J.\u00a0Alzheimer\u2019s Dis."},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib44","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3233\/JAD-150487","article-title":"Older adults taking AT1-receptor blockers exhibit reduced cerebral amyloid retention","volume":"50","author":"Nation","year":"2016","journal-title":"J.\u00a0Alzheimers. Dis."},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib45","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1460-9568.2005.03912.x","article-title":"The N-terminal active centre of human angiotensin-converting enzyme degrades Alzheimer amyloid \u03b2-peptide","volume":"21","author":"Oba","year":"2005","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib46","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2174\/1567205014666171016101816","article-title":"Pharmacogenetics of angiotensin-converting enzyme inhibitors in patients with Alzheimer\u2019s disease dementia","volume":"15","author":"Oliveira","year":"2018","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib47","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1038\/s41467-017-01150-x","article-title":"Earliest accumulation of \u03b2-amyloid occurs within the default-mode network and concurrently affects brain connectivity","volume":"8","author":"Palmqvist","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib48","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41569-019-0244-8","article-title":"Counter-regulatory renin-angiotensin system in cardiovascular disease","volume":"17","author":"Paz Ocaranza","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib49","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3390\/ijms17030347","article-title":"Hypertension and dementia: epidemiological and experimental evidence revealing a detrimental relationship","volume":"17","author":"Perrotta","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib50","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1212\/WNL.0000000000008732","article-title":"Investigation of antihypertensive class, dementia, and cognitive decline","volume":"94","author":"Peters","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib51","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jagp.2012.08.017","article-title":"Angiotensin converting enzyme inhibitors and Alzheimer disease in the presence of the apolipoprotein E4 allele","volume":"22","author":"Qiu","year":"2014","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib52","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.neurobiolaging.2019.05.005","article-title":"Synergism between fornix microstructure and beta amyloid accelerates memory decline in clinically normal older adults","volume":"81","author":"Rabin","year":"2019","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib53","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/ana.25399","article-title":"Vascular risk and \u03b2-amyloid are synergistically associated with cortical tau","volume":"85","author":"Rabin","year":"2019","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib54","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI114844","article-title":"An insertion\/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels","volume":"86","author":"Rigat","year":"1990","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib55","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/ajhp\/58.8.671","article-title":"Angiotensin II-receptor blockers: clinical relevance and therapeutic role","volume":"58","author":"Rodgers","year":"2001","journal-title":"Am. J. Heal. Pharm."},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib56","first-page":"16","article-title":"Does the angiotensin-converting enzyme (ACE) gene insertion\/deletion polymorphism modify the response to ACE inhibitor therapy? A systematic review","volume":"6","author":"Scharplatz","year":"2005","journal-title":"Curr. Control Trials Cardiovasc. Med."},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib57","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1161\/HYPERTENSIONAHA.109.138586","article-title":"Angiotensin receptor blocker prevented \u03b2-amyloid-induced cognitive impairment associated with recovery of neurovascular coupling","volume":"54","author":"Shuko","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib58","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0140-6736(96)90608-X","article-title":"15-year longitudinal study of blood pressure and dementia","volume":"347","author":"Skoog","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib59","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/brain\/awy327","article-title":"Polygenic hazard score, amyloid deposition and Alzheimer\u2019s neurodegeneration","volume":"142","author":"Tan","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib60","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1161\/CIRCRESAHA.118.313563","article-title":"Getting to the heart of Alzheimer disease","volume":"124","author":"Tublin","year":"2019","journal-title":"Circ. Res."},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib61","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1056\/NEJMsr2005760","article-title":"Renin\u2013angiotensin\u2013aldosterone system inhibitors in patients with Covid-19","volume":"382","author":"Vaduganathan","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib62","first-page":"1","article-title":"ipw: an R package for inverse probability weighting","volume":"1","author":"van der Wal","year":"2011","journal-title":"J.\u00a0Stat. Softw."},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib63","doi-asserted-by":"crossref","first-page":"E1807","DOI":"10.1073\/pnas.1220484110","article-title":"ApoE influences amyloid-\u03b2 (A\u03b2) clearance despite minimal apoE\/A\u03b2 association in physiological conditions","volume":"110","author":"Verghese","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib64","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","article-title":"Amyloid \u03b2 deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer\u2019s disease: a prospective cohort study","volume":"12","author":"Villemagne","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib65","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/ije\/dyz155","article-title":"Repurposing antihypertensive drugs for the prevention of Alzheimer\u2019s disease: a Mendelian randomization study","volume":"49","author":"Walker","year":"2019","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib66","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1172\/JCI31547","article-title":"Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease","volume":"117","author":"Wang","year":"2007","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib67","doi-asserted-by":"crossref","first-page":"4368474","DOI":"10.1155\/2017\/4368474","article-title":"Association between antihypertensive drug use and the incidence of cognitive decline and dementia: a meta-analysis of prospective cohort studies","volume":"2017","author":"Xu","year":"2017","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib68","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1212\/WNL.0b013e3182a35228","article-title":"Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo evaluation of memory study","volume":"81","author":"Yasar","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2020.12.011_bib69","doi-asserted-by":"crossref","first-page":"8628","DOI":"10.1523\/JNEUROSCI.1549-07.2007","article-title":"Angiotensin-converting enzyme converts amyloid \u03b2-protein 1\u201342 (A\u03b21\u201342) to A\u03b21\u201340, and its inhibition enhances brain A\u03b2 deposition","volume":"27","author":"Zou","year":"2007","journal-title":"J.\u00a0Neurosci."}],"container-title":["Neurobiology of Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019745802030422X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019745802030422X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T11:35:01Z","timestamp":1759318501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019745802030422X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":69,"alternative-id":["S019745802030422X"],"URL":"https:\/\/doi.org\/10.1016\/j.neurobiolaging.2020.12.011","relation":{},"ISSN":["0197-4580"],"issn-type":[{"value":"0197-4580","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Associations between brain amyloid accumulation and the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Aging","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurobiolaging.2020.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}